Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

12 March 2002

Eradication of Helicobacter pylori in duodenal ulcer disease tetracycline & furazolidone vs. metronidazole & amoxicillin in omeprazole based triple therapy.

Mohammad S Fallah, Fariborz Mansour-Ghanaei, Afshin Shafaghi

Med Sci Monit 2002; 8(3): PI27-30 :: ID: 420887

Abstract

BACKGROUND: The object of the study was to study the efficacy and safetyof furazolidone and tetracycline compared to metronidazole and amoxicillin in an omeprazole based tripletherapy in a prospective randomized-blind-clinical trial. MATERIAL/METHODS: Patients with endoscopicallyverified active duodenal ulcer disease in the presence of Helicobacter pylori infection were eligibleto enter the study. Endoscopy was performed a day before and 6-8 weeks after the cessation of treatment.H. pylori status was assessed by histologic examination (Giemsa stain) of biopsy specimens were takenfrom the antrum and corpus. H. pylori eradication was defined as absence in histology of the biopsy specimensat the second endoscopy. Ulcer healing was considered as decrease in ulcer size to less than 20% of itsprimary size. Patients were randomly assigned to receive omeprazole 20 mg, amoxicillin 1000 mg and metronidazole500 mg (OAM group) or omeprazole 20 mg, tetracycline 500 mg and furazolidone 200 mg (OTF group). Allmedications were taken twice daily, for 2 weeks. RESULTS: Out of 111 patients enrolled in the study,108 completed a course of treatment and underwent a follow-up endoscopy, with 54 patients in each group.H. pylori eradication was achieved in 52 patients (96.3% - 95% CI: 91.27-100) in OTF group and 45 patients(83.3% - 95% CI: 73.35-93.25) in OAM group (P=0.015). Our study showed the superiority of OTF vs. OAMregimen with a 13% increment in eradication rate, with only occasional severe side effect. CONCLUSIONS:In conclusion OTF regimen is a safe, cheaper and effective alternative for OTF regimen and we recommendit to be used especially in developing countries.

Keywords: Amoxicillin, Anti-Bacterial Agents, Anti-Infective Agents, Local, Antibiotics, Combined, Duodenal Ulcer, furazolidone, Helicobacter pylori, metronidazole, Tetracycline

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

26 Feb 2024 : Clinical Research  

Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...

Med Sci Monit In Press; DOI: 10.12659/MSM.942509  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750